7:20AM Alimera Sciences' ILUVIEN receives marketing authorization in Germany for the treatment of chronic diabetic macular edema (ALIM) 2.89 : This marketing authorization follows the completion of the Decentralized Regulatory Procedure (DCP), in which the Medicines and Healthcare products Regulatory Agency in the United Kingdom, serving as the Reference Member State, delivered a positive outcome for ILUVIEN along with six Concerned Members States, which include Austria, France, Germany, Italy, Spain and Portugal. The German authorization is the fifth national approval in the EU, preceded by Austria, Portugal, the U.K. and France.
Market Data 
Markets 
